Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

93.33 -1.29 (-1.36%)
Streaming Delayed Price Updated: 1:44 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal ↗
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... 
Via Talk Markets
News headline image
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.